StockNews.com Initiates Coverage on Harvard Bioscience (NASDAQ:HBIO)

Equities researchers at StockNews.com started coverage on shares of Harvard Bioscience (NASDAQ:HBIO) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.

Several other research analysts have also recently issued reports on the company. Benchmark decreased their price target on Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating for the company in a research note on Monday, March 24th. KeyCorp reiterated a “sector weight” rating on shares of Harvard Bioscience in a research note on Wednesday, April 9th.

Harvard Bioscience Stock Performance

Shares of HBIO stock opened at $0.40 on Friday. Harvard Bioscience has a 12-month low of $0.36 and a 12-month high of $4.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91. The firm has a market capitalization of $17.63 million, a price-to-earnings ratio of -1.21 and a beta of 1.47. The business has a 50 day simple moving average of $0.82 and a 200 day simple moving average of $1.72.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. State Street Corp boosted its stake in shares of Harvard Bioscience by 1.1% during the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after acquiring an additional 7,763 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Harvard Bioscience by 63.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 11,397 shares in the last quarter. Bank of America Corp DE raised its holdings in Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after buying an additional 11,948 shares during the period. Jane Street Group LLC lifted its stake in Harvard Bioscience by 55.5% during the fourth quarter. Jane Street Group LLC now owns 35,769 shares of the medical instruments supplier’s stock valued at $75,000 after buying an additional 12,767 shares in the last quarter. Finally, Focus Partners Wealth purchased a new position in shares of Harvard Bioscience in the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.